225 related articles for article (PubMed ID: 12868802)
1. Neoadjuvant docetaxel in locally advanced breast cancer.
Hutcheon AW; Heys SD; Sarkar TK;
Breast Cancer Res Treat; 2003; 79 Suppl 1():S19-24. PubMed ID: 12868802
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
Smith IC; Heys SD; Hutcheon AW; Miller ID; Payne S; Gilbert FJ; Ah-See AK; Eremin O; Walker LG; Sarkar TK; Eggleton SP; Ogston KN
J Clin Oncol; 2002 Mar; 20(6):1456-66. PubMed ID: 11896092
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.
Heys SD; Hutcheon AW; Sarkar TK; Ogston KN; Miller ID; Payne S; Smith I; Walker LG; Eremin O;
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S69-74. PubMed ID: 12435290
[TBL] [Abstract][Full Text] [Related]
5. Primary chemotherapy with docetaxel for the management of breast cancer.
Valero V
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):35-43. PubMed ID: 12108896
[TBL] [Abstract][Full Text] [Related]
6. The role of taxanes in the adjuvant treatment of early stage breast cancer.
Piccart M
Breast Cancer Res Treat; 2003; 79 Suppl 1():S25-34. PubMed ID: 12868803
[TBL] [Abstract][Full Text] [Related]
7. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
8. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival.
Heys SD; Sarkar T; Hutcheon AW
Breast Cancer Res Treat; 2005 Mar; 90(2):169-85. PubMed ID: 15803364
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience.
Tiwari A; Gogia A; Deo S; Shukla NK; Mathur S; Sharma DN
Indian J Cancer; 2017; 54(1):343-346. PubMed ID: 29199719
[TBL] [Abstract][Full Text] [Related]
10. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
11. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
12. The European experience with docetaxel in the treatment of early-stage breast cancer.
Di Leo A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S59-62. PubMed ID: 12435289
[TBL] [Abstract][Full Text] [Related]
13. Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer.
Gradishar WJ
Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S31-5. PubMed ID: 11970742
[TBL] [Abstract][Full Text] [Related]
14. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
15. Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel-refractory metastatic breast cancer.
Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
Breast Cancer; 2002; 9(2):166-9. PubMed ID: 12016397
[TBL] [Abstract][Full Text] [Related]
16. From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer.
Abdel-Razeq H; Marei L; Saadeh SS; Abdulelah H; Abu-Nasser M; Salam M; Daana W; Al-Haj Ali B; Taqash A
Breast Cancer Res Treat; 2017 Oct; 165(3):771-777. PubMed ID: 28667456
[TBL] [Abstract][Full Text] [Related]
17. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
[TBL] [Abstract][Full Text] [Related]
18. [Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
Wenzel C; Schmidinger M; Locker GJ; Taucher S; Gnant M; Jakesz R; Steger GG
Wien Klin Wochenschr; 1999 Oct; 111(20):843-50. PubMed ID: 10586489
[TBL] [Abstract][Full Text] [Related]
19. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience.
Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
Asian Pac J Cancer Prev; 2014; 15(5):1989-92. PubMed ID: 24716923
[TBL] [Abstract][Full Text] [Related]
20. Treatment for anthracycline-pretreated metastatic breast cancer.
O'Shaughnessy J; Twelves C; Aapro M
Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
